VEXABAX is a combination of two nucleoside analogues (abacavir and lamivudine). It is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age, weighing at least 40 kg.
Reg. No. : 54/20.2.8/0219
Schedule 4
Each tablet contains Abacavir Sulphate 600 mg and Lamivudine 300 mg.
Atenef is indicated for the use alone as a complete regimen or in combination with other anti-retroviral agents for the treatment of HIV-1 infection in adults
Reg. No. 47/20.2.8/0483.
Schedule 4
Each tablet contains Tenofovir 300 mg, Emtricitabine 200 mg and Efavirenz 600 mg
Dosage: Once a day on an empty stomach
Sonke Efavirenz 200
Reg. No. A40/20.2.8/0507
Schedule 4
Each film-coated tablet contains Efavirenz 200 mg
Sugar free
Dosage: Evening
Sonke Efavirenz 600
Reg. No. A40/20.2.8/0508
Schedule 4
Each capsule contains Efavirenz 200 mg
Dosage: Evening
Sonke Lamivudine 150
Reg. No. A40/20.2.8/0272
Schedule 4
Each film-coated tablet contains Lamivudine 150 mg